Biogen’s Alzheimer’s hopeful aducanumab faces ‘less than a coin flip’s chance’ of FDA approval: anal

Discussion in 'Eisai' started by anonymous, Apr 21, 2021 at 7:42 PM.

Tags: Add Tags

  1. anonymous

    anonymous Guest

    I like those odds.
     
  2. anonymous

    anonymous Guest

    Absolutely, if I were a patient that is exactly what I would like to hear, "it's a flip of a coin" whether this will be good for you or not. So that's what we are hoping for, a flip of a coin? Sounds like good medicine to me.
     
  3. anonymous

    anonymous Guest

    It’s better than what Eisai usually manages.
     
  4. anonymous

    anonymous Guest

    Alex did the dude.
     
  5. anonymous

    anonymous Guest

    Did Halaven get approval in lung yet?
     
  6. anonymous

    anonymous Guest

    What do you think?
     
  7. anonymous

    anonymous Guest

    Tic toc...
     
  8. anonymous

    anonymous Guest

    I never thought it would happen. I am the one that said it would not get approved, ever!
    Now I think it may because they are talking about the price. Would anyone use this on a patient? Maybe as a last resort.
     
  9. anonymous

    anonymous Guest

    Most don’t want or think it should be approved, are hesitant to use if it is because of the serious side effects and believe it’s worth a fraction of the predicted price. That doesn’t sound like a recipe for success.
     
  10. anonymous

    anonymous Guest

    Ugh
     
  11. anonymous

    anonymous Guest

    I was contacted by a recruiter for an “opening” that was filled supposedly two months ago. Are people quitting?
     
  12. anonymous

    anonymous Guest

    The smart ones are.
     
  13. anonymous

    anonymous Guest

    People here quit as fast as they can find a new job. There isn't a long term future here. It's just not a career place unless you can't find something else.